To assess in children the efficacy and safety of 2 dosing regimens of T1225 1.5% eye drops, in comparison to a reference product, single-dose oral azithromycin (AZM) 20 mg/kg, for the treatment of active trachoma. Evaluation of clinical efficacy was primary (% of clinical cure at Day 60 in Per Protocol Set), microbiological evaluation was secondary

The aim of the present study was to compare the efficacy of the dosing regimen which was demonstrated in pharmacokinetic studies to be the best candidate for trachoma treatment (T1225 1.5% eye drops BID for 3 days) with a shorter duration of treatment (T1225 1.5% eye drops BID for 2 days) and with a single oral administration of AZM (20 mg/kg) in patients suffering from active trachoma. The study was to be performed in approximately 600 children (aged 1 to 10 years) from Guinea Conakry and Pakistan.

Inclusion Criteria:

• Male or female aged 1-10 years;
• written informed consent by legally acceptable representative;
• TF+ TI0 (trachomatous inflammation - follicular) or TF+TI+ (trachomatous inflammation - follicular and intense) on simplified World Health Organisation (WHO) grading system

Exclusion Criteria:

• Trichiasis or corneal opacity;
• palpebral deformation;
• clinically significant ocular abnormality;
• ocular infection;
• organic amblyopia;
• hypersensitivity to treatments' components;
• immunosuppressive conditions;
• systemic AZM or steroids;
• topical ophthalmic antibiotics within 3 months;
• other systemic antibiotics within 1 month;
• topical (ocular, nasal, bronchial etc.) treatments within 1 week;
• systemic non-steroidal anti-inflammatory drugs on day before Day 0